Palatin Technologies (Palatin Technologies) Debt-to-Equity : -0.07 (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Palatin Technologies Debt-to-Equity?

Palatin Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.46 Mil. Palatin Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.36 Mil. Palatin Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-11.38 Mil. Palatin Technologies's debt to equity for the quarter that ended in Dec. 2023 was -0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Palatin Technologies's Debt-to-Equity or its related term are showing as below:

PTN' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.19 Med: 0.05 Max: 7.84
Current: -0.07

During the past 13 years, the highest Debt-to-Equity Ratio of Palatin Technologies was 7.84. The lowest was -4.19. And the median was 0.05.

PTN's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs PTN: -0.07

Palatin Technologies Debt-to-Equity Historical Data

The historical data trend for Palatin Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palatin Technologies Debt-to-Equity Chart

Palatin Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.03

0.07

7.84

Palatin Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.06	0.08	7.84	-0.19	-0.07

Competitive Comparison of Palatin Technologies's Debt-to-Equity

For the Biotechnology subindustry, Palatin Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Palatin Technologies's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palatin Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Palatin Technologies's Debt-to-Equity falls into.

Palatin Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Palatin Technologies's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.46	+	0.59)	/	0.134
	=	7.84

Palatin Technologies's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.464	+	0.358)	/	-11.384
	=	-0.07

Palatin Technologies (AMEX:PTN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Palatin Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Palatin Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Palatin Technologies (Palatin Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (AMEX:PTN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PTN:Germany PTN:Germany

Address

4B Cedar Brook Drive, Cranbury, NJ, USA, 08512

Website

https://www.palatin.com

Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.

Executives

Stephen T Wills	officer: Executive Vice President, CFO	PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Alan W Dunton	director	VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Carl Spana	director, officer: President and CEO	PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Deveer Robert K Jr	director	C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Joseph Stanley Hull	director	PALATIN TECHNOLOGIES INCORPORATED, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Arlene Morris	director	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Anthony M. Manning	director	C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Angela Rossetti	director	PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Robert I Taber	director	C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Zola P Horovitz	director	C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Perry B Molinoff	director, officer: Exec. VP Research and Devel.	C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104